AQST News and Press, Aquestive Therapeutics Inc. From 05/31/23

2023-05-31 11:07:40 ET Aquestive Therapeutics released clinical data from recent pilot studies on Anaphylm, a sublingual film for the treatment of anaphylaxis. The studies showed that Anaphylm achieved a maximum blood concentration (Tmax) in a median time of 10 minutes, ranging from 5...

Time to maximum blood concentration (median Tmax) for Anaphylm was 10 minutes with a range of 5 to 20 minutes Early drug exposure at 10 minutes (partial area under the curve, or pAUC 0-10min ) for Anaphylm was similar to Auvi-Q® (epinephrine injection) auto-injector 0.3mg a...

2023-05-12 13:14:08 ET Gainers: GSI Technology ( GSIT ) +149% . ARS Pharmaceuticals ( SPRY ) +80% . Zapp Electric Vehicles Group Limited ( ZAPP ) +42% . AirSculpt Technologies ( AIRS ) +39% . Blue Bird Corporation ( BLBD ) +34% ....

2023-05-03 10:35:06 ET Aquestive Therapeutics, Inc. (AQST) Q1 2023 Earnings Conference Call May 03, 2023, 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, C...

2023-05-02 17:11:24 ET Aquestive Therapeutics press release ( NASDAQ: AQST ): Q1 GAAP EPS of $0.11. Revenue of $11.13M (-9.3% Y/Y) beats by $1.19M . Now sees FY 2023 revenue of $42M to $46M from $37M to $41M previously. The consensus estimate is $39.06M. For ...

Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™ Raises full year 2023 revenue and non-GAAP adjusted EBITDA guidance Reaffirms commitment to pursue early market access for Libervant™ (diazep...

2023-04-20 10:42:57 ET Aquestive Therapeutics ( NASDAQ: AQST ) disclosed that the FDA has conditionally sanctioned Anaphylm as the proposed brand name for AQST-109, which is used to treat severe allergic reactions, particularly anaphylaxis. The proprietary name Anaphylm was de...

WARREN, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative produc...

WARREN, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative produ...

2023-03-29 09:15:13 ET Aquestive Therapeutics ( NASDAQ: AQST ) expanded its exclusive license and supply agreement with Atnahs Pharma UK (Pharmanovia) for seizure therapy Libervant (diazepam) Buccal Film. The expanded agreement will cover the rest of the world, e...